Issuers will hope the outperformance continues, as consensus is now that there will be no EPS growth in Q1. Bank of America ...

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

DIsney says it has sold out all commercial inventory for Sunday's Oscars, and notes packages include TV, streaming, social ...

Full year 2024 revenue of $807 million, exceeding guidance - - All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Q4 2024 Earnings Call Transcript February 26, 2025 Standard BioTools Inc. misses on earnings expectations. Reported EPS is $-0.09097 EPS, expectations were $-0.07. Operator: Good day, everyone, and ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Reports Q4 revenue $88.3M, consensus $83.2M. “We are delighted with Schrodinger’s (SDGR) excellent financial performance in 2024. Software ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 & is estimated to hit $35.9 billion by 2032, exhibiting a CAGR of 28 ...